Greg Winter

From Wikipedia, the free encyclopedia

Sir Gregory Winter FRS is a British pioneer of therapeutic monoclonal antibodies. He invented techniques to both humanise (1986) and, later, to fully-humanise, antibodies for therapeutic uses.

Before this groundbreaking work antibodies had failed to live up to their potential because they had been derived from mice. In 1989 Winter was a founder of Cambridge Antibody Technology, which was one of the early commercial biotech companies involved in antibody engineering.

In 2000 Winter founded a company called Domantis to pioneer the use of domain antibodies, which use only the active portion of a full-sized antibody. In 1995 Winter won the King Faisal International Prize for Medicine (Molecular Immunology). Winter is currently the Joint Head of the Division of Protein and Nucleic Acid Chemistry-Biotechnology, and is also Acting Director^[1], at the Laboratory of Molecular Biology, Cambridge, an institution funded by the UK Medical Research Council. He is also Deputy Director of the MRC’s Centre for Protein Engineering. Winter was knighted in 2004. He is a Fellow of Trinity College, University of Cambridge.

[edit] Notes & References

1. ^ LMB Structure